Amyloid– tag –
-
FDA Lifts Clinical Hold on Intellia Therapeutics’ Phase 3 Trial for nex-z in Transthyretin Amyloidosis
Intellia Therapeutics (via LinkedIn) USA Overview Intellia Therapeutics announced the FDA has lifted the clinical hold on its Phase 3 MAGNITUDE-2 clinical trial for nexiguran ziclumeran (nex-z), a therapeutic candidate for transthyretin ... -
Voyager Therapeutics Advances Two Tau-Targeted Alzheimer’s Therapies Towards Key Clinical Milestones
NeurologyLive USA Overview Voyager Therapeutics announced its progression of two innovative therapeutic candidates targeting tau protein, a key pathological hallmark of Alzheimer's disease, toward significant clinical milestones. These c...
1